Cite

HARVARD Citation

    Gold, R. et al. (2016). Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC neurology. 16 (1), pp. 1-10. [Online]. 
  
Back to record